FARMERS & MERCHANTS TRUST Co OF LONG BEACH Has $4.42 Million Stock Holdings in Amgen Inc. (NASDAQ:AMGN)

FARMERS & MERCHANTS TRUST Co OF LONG BEACH boosted its position in Amgen Inc. (NASDAQ:AMGN) by 1.5% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 20,761 shares of the medical research company’s stock after buying an additional 314 shares during the quarter. Amgen makes up about 1.2% of FARMERS & MERCHANTS TRUST Co OF LONG BEACH’s portfolio, making the stock its 17th biggest position. FARMERS & MERCHANTS TRUST Co OF LONG BEACH’s holdings in Amgen were worth $4,415,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Birch Capital Management LLC boosted its stake in shares of Amgen by 3.4% during the 2nd quarter. Birch Capital Management LLC now owns 21,721 shares of the medical research company’s stock worth $5,295,000 after acquiring an additional 708 shares during the period. Silvercrest Asset Management Group LLC lifted its holdings in Amgen by 1.0% during the 2nd quarter. Silvercrest Asset Management Group LLC now owns 364,468 shares of the medical research company’s stock worth $88,840,000 after purchasing an additional 3,546 shares during the last quarter. Arlington Financial Advisors LLC lifted its holdings in Amgen by 8.3% during the 2nd quarter. Arlington Financial Advisors LLC now owns 25,724 shares of the medical research company’s stock worth $6,270,000 after purchasing an additional 1,962 shares during the last quarter. Mather Group LLC. lifted its holdings in Amgen by 25.4% during the 2nd quarter. Mather Group LLC. now owns 5,591 shares of the medical research company’s stock worth $1,363,000 after purchasing an additional 1,134 shares during the last quarter. Finally, Calamos Advisors LLC lifted its holdings in Amgen by 29.4% during the 2nd quarter. Calamos Advisors LLC now owns 77,154 shares of the medical research company’s stock worth $18,806,000 after purchasing an additional 17,549 shares during the last quarter. 74.95% of the stock is currently owned by institutional investors and hedge funds.

Several equities analysts have weighed in on the company. SVB Leerink dropped their price objective on Amgen from $234.00 to $216.00 and set a “market perform” rating for the company in a report on Wednesday, November 3rd. Oppenheimer dropped their price objective on Amgen from $277.00 to $272.00 and set an “outperform” rating for the company in a report on Monday, November 1st. Daiwa Capital Markets cut Amgen from an “outperform” rating to a “neutral” rating and set a $220.00 price objective for the company. in a report on Thursday, September 23rd. BMO Capital Markets assumed coverage on Amgen in a report on Thursday, November 18th. They issued a “market perform” rating and a $228.00 price objective for the company. Finally, Mizuho dropped their price objective on Amgen from $222.00 to $194.00 and set a “neutral” rating for the company in a report on Monday. Two analysts have rated the stock with a sell rating, ten have assigned a hold rating and six have given a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $235.50.

Shares of NASDAQ AMGN traded down $0.56 during trading on Thursday, reaching $203.97. The company had a trading volume of 1,699,089 shares, compared to its average volume of 2,617,473. The company’s fifty day moving average price is $209.99 and its 200-day moving average price is $227.76. Amgen Inc. has a 12 month low of $200.47 and a 12 month high of $276.69. The stock has a market cap of $114.89 billion, a P/E ratio of 21.01, a PEG ratio of 1.47 and a beta of 0.61. The company has a quick ratio of 1.36, a current ratio of 1.64 and a debt-to-equity ratio of 4.05.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, November 2nd. The medical research company reported $4.67 EPS for the quarter, beating analysts’ consensus estimates of $4.22 by $0.45. Amgen had a return on equity of 108.67% and a net margin of 21.77%. During the same period last year, the firm posted $4.37 EPS. As a group, equities analysts predict that Amgen Inc. will post 16.83 earnings per share for the current year.

The business also recently declared a quarterly dividend, which will be paid on Wednesday, December 8th. Shareholders of record on Tuesday, November 16th will be given a $1.76 dividend. The ex-dividend date of this dividend is Monday, November 15th. This represents a $7.04 dividend on an annualized basis and a dividend yield of 3.45%. Amgen’s dividend payout ratio (DPR) is presently 72.50%.

Amgen Company Profile

Amgen, Inc is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, Aimovig, KANJINTI, EVENITY, AMGEVITA, AVSOLA, BLINCYTO, MVASI, Corlanor, Enbrel, EPOGEN, IMLYGIC, Kyprolis, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, Otezla, RIABNI, and XGEVA.

Featured Article: How Buying a Call Option Works

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.